DC-05F01 is under clinical development by Beijing Shuanghe Runchuang Technology and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DC-05F01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DC-05F01 is under development for the treatment of metastatic solid tumors. It is administered through oral route.
Beijing Shuanghe Runchuang Technology overview
Beijing Shuanghe Runchuang Technology (Shuanghe Runchuang Technology) operate in healthcare sector. Shuanghe Runchuang Technology is headquartered in Beijing, China.
For a complete picture of DC-05F01’s drug-specific PTSR and LoA scores, buy the report here.